The publications contained in this archive section are provided for historical purposes only. The views expressed in the publications are those of their respective authors and do not reflect the views of NOXXON. NOXXON disavows any obligation to update or correct the information contained in these publications.

Riecke K, Ludwig H, van Eijk L, Boyce M, Pickkers P, Macdougall I, Schwöbel F, Swinkels D.
Clinical Pharmacology, Efficacy, and Safety of the Anti-Hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94).

European Iron Club
2014, Verona
Presentation

Georgiev P, Lazaroiu M, Ocroteala L, Grudeva-Popova J, Gheorghita E, Vasilica M, Popescu S, Cucuianu A, Summo L, Schwoebel F, Riecke K, Ludwig H.
The Anti-Hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94) as Treatment of Anemia of Chronic Disease in Patients with Multiple Myeloma, Low Grade Lymphoma, and CLL: a Phase II pilot Study.

European Hematology Association
2014, Milan
Poster

Steurer M, Montillo M, Scarfò L, Mauro FR, Andel J, Wildner S, Trentin L, Janssens A, Burgstaller S, Kruschinski A, Dümmler T, Riecke K, Ghia P, Caligaris-Cappio F, Gobbi M.
Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia.

ASH
2014, San Francisco
Poster

Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Garderet L, Zojer N, Riecke K, Kruschinski A, Dümmler T, Foa R, Greil R, Yakoub-Agha I, Engelhardt M.
Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma.

ASH
2014, San Francisco
Poster

Zboralski D, Vater A, Kruschinski A.
Comparison of Ibrutinib, Idelalisib and Olaptesed Pegol on the Immune Effector Function Mediated by Rituximab and Obinutuzumab.

ASH
2014, San Francisco
Poster

Georgiev P, Lazaroiu M, Ocroteala L, Grudeva-Popova J, Gheorghita E, Vasilica M, Popescu SM, Cucuianu A, Summo L, Schwoebel F, Riecke K, Ludwig H.
The anti-hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study.
Cancer Research. 2014, 74, 3847.
read abstract on aacrjournals.org

van Eijk LT, John AS, Schwoebel F, Summo L, Vauléon S, Zöllner S, Laarakkers CM, Kox M, van der Hoeven JG, Swinkels DW, Riecke K, Pickkers P.
Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans.
Blood. 2014, 124(17), 2643-6.
read article on bloodjournal.org

Steinbicker AU.
Comment on van Eijk et al
A novel treatment of anemia of inflammation.

Blood.
2014, 124(17), 2618-19.
read comment on bloodjournal.org

Roccaro et al.
SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy.
Cell Reports. 2014, 9(1), 118-28.
read article on cell.com

Purschke WG, Hoehlig K, Buchner K, Zboralski D, Schwoebel F, Vater A, Klussmann S.
Identification and characterization of a mirror-image oligonucleotide that binds and neutralizes Sphingosine-1-Phosphate, a central mediator of angiogenesis.

Biochemical J.
2014, 462(1), 153-62.
read article on biochemj.org

Jerlhag E, Ivanoff L, Vater A, Engel JA.
Peripherally circulating ghrelin does not mediate alcohol-induced reward and alcohol intake in rodents.

Alcohol Clin Exp Res.
2014, 38(4), 959-68.
read article on wiley.com

Ehling J, Bartneck M, Wei X, Gremse F, Fech V, Möckel D, Baeck C, Hittatiya K, Eulberg D, Luedde T, Kiessling F, Trautwein C, Lammers T, Tacke F.
CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis.

Gut.
2014, 63(12), 1960-71.
view PubMed abstract on ncbi.nlm.nih.gov

Baeck C, Wei X, Bartneck M, Fech V, Heymann F, Gassler N, Hittatiya K, Eulberg D, Luedde T, Trautwein C, Tacke F.
Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C+ macrophage infiltration in mice.

Hepatology.
2014,59(3), 1060-72.
read abstract on wiley.com

Yamamoto H, Qin Y, Achenbach J, Li C, Kijek J, Spahn CM, Nierhaus KH.
EF-G and EF4: translocation and back-translocation on the bacterial ribosome.

Nat Rev Microbiol.
2014, 12, 89-100.
read abstract on nature.com

Liu S-C, Alomran R, Chernikova SB, Lartey F, Stafford J, Jang T, Merchant M, Zboralski D, Zöllner S, Kruschinski A, Klussmann S, Recht L, Brown JM.
Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats.

Neuro-Oncology.
2014, 16(1), 21-28.
read article on oxfordjournals.org

Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, Kruschinski A, Burger JA.
The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization.

Blood.
2014, 123(7), 1032-1039.
view abstract on hematologylibrary.org

Marasca R, Maffei R.
Comment on Hoellenriegel et al
NOX-A12: mobilizing CLL away from home.

Blood.
2014, 123(7), 952-953.
read comment on hematologylibrary.org